In April 2018, the Centers for Disease Control and Prevention (CDC) released a report estimating the prevalence of autism spectrum disorder (ASD) in the United States at 1 in 59 children. The figure was based on a 2014 survey of eight-year-old children across 11 residential communities in the country, so clearly it was out of date. It was not a valid estimate of the prevalence of ASD in the U.S. in 2017 or 2018,1 and we don’t know what the figure is for 2019.
As pediatrician Bob Sears, MD notes, the “main drawback” of this methodology by the CDC is that it takes “many years to research and report data this way, and the information is very old by the time we get it.” Dr. Sears adds:
For example, for kids born in 2004, the CDC had to wait until they were are 8 years old (2012), then take two years to gather the data on diagnosis rates, then publish it. So, we didn’t learn the rate of autism in these kids until 10 years after they are born.2
So long as the methodology (notably the four-year lag time and the focus on eight-year-olds) used by the CDC is known and understood, it is not a problem. The public just needs to be aware that the CDC’s autism prevalence figure is always going to be out of date by the time it is released.
A better source for more current information on the prevalence of autism in the U.S. is the National Health Center for Health Statistics (NCHS), which is the U.S. government’s principal health statistics agency.3
The NCHS conducts nationwide surveys to tabulate health data on different topics, including estimates for how prevalent autism is among children. In 2017, the NCHS published health data for 2014-2016 which pegged the prevalence of autism for children aged 3-17 years at 1 in 36 in 2016, compared to 1 in 43 in 2015 and 1 in 45 in 2014.2
As of 2017, the 1 in 36 figure appeared to be the most current estimate from the U.S. government for the prevalence of autism, not the 1 in 59 figure that has been so commonly cited by the media and other sources for the past year.4 5 6 7
To make things slightly more confusing, there is a new autism prevalence figure in a study published in the journal Pediatrics in December 2018 based on the 2016 National Survey of Children’s Health (NSCH). That study estimates that 1 in 40 children have autism. The NSCH is funded and directed by the Maternal and Child Health Bureau (MCHB) of the Health Resources and Services Administration (HRSA).8 9 10
1 Parpia R, Fisher BL. CDC: Autism Rate Going Up. The Vaccine Reaction May 28, 2018.
2 Sears R. Autism Rate Jumps to 1 in 36 Children, 1 in 28 Boys. AskDrSears.
3 National Center for Health Statistics (NCHS). U.S. National Library of Medicine.
4 University of Central Florida. Processed foods and effect on developing fetus’ brain: Autism link? Science Daily June 20, 2019.
5 How Common is Autism? Autism Science Foundation.
6 Staff News Writer. Wearable tech supports home therapy for kids with autism. American Medical Association June 21, 2019.
7 Max. I Have Autism and I’m Offended by the Anti-Vax Movement. Newsweek June 19, 2019.
8 Mozes A. Report: Autism Rate Rises to 1 in 40 Children. HealthDay Nov. 26, 2018.
9 Kogan MD, Vladutiu CJ, Schieve LA, Ghandour RM, Blumberg SJ, Zablotsky B, Perrin JM, Shattuck P, Kuhlthau KA, Harwood RL, Lu MC. The Prevalence of Parent-Reported Autism Spectrum Disorder Among US Children. Pediatrics December 2018; 142(6).
10 The National Survey of Children’s Health. Data Resource Center for Child & Adolescent Health.
For more: https://madisonarealymesupportgroup.com/2019/06/13/blast-from-the-past-cdc-vaccine-authors-destroy-evidence-of-vaccine-harm/ CDC scientist William Thompson admitted scientists purposely destroyed data.
“The omitted data suggested that African-American males whoreceived the MMR vaccine before age 36 months were at increasedrisk for autism.” Dr. William Thompson
Published on Oct 29, 2015
“The omitted data suggested that African-American males whoreceived the MMR vaccine before age 36 months were at increasedrisk for autism.” Dr. William Thompson
“Decisions were made regarding the findings of the report that thedata was collected and I believe that the final study protocol was notfollowed.” Dr. William Thompson
For more: https://madisonarealymesupportgroup.com/2016/11/29/spider-attacks-cdc/ This article lists case by case of CDC fraud and corruption.
https://madisonarealymesupportgroup.com/2017/09/27/strange-case-of-poul-thorsen-vaccine-data-manipulator-extraordinaire/ “When the CDC was notified by Thorsen’s Denmark colleagues about inaccuracies regarding CDC grants and funding, further investigation resulted “in 22 federal criminal counts – 13 counts of wire fraud and 9 counts of money laundering,” which never have been acted upon by the USA or CDC. Thorsen is hiding in plain sight, working and publishing articles in Denmark, with no extradition apparently requested by the CDC! How strange? “The United States has had an Extradition Treaty with Denmark since the Nixon Administration (1974).” (Pg. 4)….
the Danish medical researcher who produced the ‘premiere safety study’ that vaccines do not cause Autism; however, the study was produced fraudulently, but the CDC still promotes it and has not retracted it from vaccinology research, as science protocol requires.”
As we are entering another April, you hardly hear much about Autism Awareness (guess everyone that counts IS aware of this terrifying pandemic), and you certainly do not hear about any better answers (medical or otherwise) for parents now, than when Autism Speaks (Feb. 2005) and so many parent groups sprang up to “help “
Sadly, it’s getting easier and easier to explain why. Over all theses year, neither those in charge of our present medical system (impossible to be innocently misdirected at this time) or these groups have wanted to admit the truth; A terrible mistake was made (and still being perpetuated), these children must have a medical disease, because most have organic (medical – motor) issues, and for the reason below do not fit or qualify for what IS being called “autism.”
IF multiple times over in the 40s, 50s, 60s, Dr. Kanner and other worldwide prominent psychiatrists argued, stood up, and fought for the idea this new idea of “autism” was unique from other childhood schizophrenias; AND unless a child met the strict criteria set up, a child did not have “autism”!!!
As discussed, many times, those strict criteria included:
IF the system won’t change, the organized groups won’t change, how many of you as parents are ready to finally change, ready to come together in the one fight NEVER done over ALL these years. Your children are ill, they do not have a DSM, psychiatric, developmental label called autism and you want immediate medical help for your children, a medical crisis that has been completely ignored for well over 24++ years.
If enough of you can come together, create a new organization focused on the right solution (starts with this is NOT autism), this April could be the start of real hope for all of you and your families. IF not, sadly safe to say, nothing is going to change . . . hope that statement is finally unacceptable to many more of you. You and your children deserve a lot more, and a real change for a better future . . . not same old, same old.
Michael Goldberg, MD
Dr. Goldberg makes very important and valid points. Without the correct definition, patients can not get appropriate treatment.
This is true in the Lyme/MSIDS world as well. Mainstream medicine is calling this complex illness “Lyme Disease,” when it typically is so much more than that.
Research has proven this is typically a polymicrobial illness causing a wide range of symptoms – each necessitating different treatment: https://madisonarealymesupportgroup.com/2018/10/30/study-shows-lyme-msids-patients-infected-with-many-pathogens-and-explains-why-we-are-so-sick/
Mainstream medicine also hasn’t admitted that borrelia alone is a formidable foe that is pleomorphic requiring different medications for each form: https://madisonarealymesupportgroup.com/2019/04/05/ability-of-stationary-phase-persister-biofilm-microcolonies-of-borrelia-burgdorferi-to-cause-more-severe-disease/
They also push the “classic EM rash” criteria, when far fewer get it than is being touted: https://madisonarealymesupportgroup.com/2019/02/22/why-mainstream-lyme-msids-research-remains-in-the-dark-ages/ Nearly ALL research being done uses the EM criteria as a starting point, leaving out thousands of patients.
Mainstream research on Lyme/MSIDS has used abysmal blood serology testing for decades, suppressing direct detection methods: https://madisonarealymesupportgroup.com/2018/10/12/direct-diagnostic-tests-for-lyme-the-closest-thing-to-an-apology-you-are-ever-going-to-get/ Again, this leaves out thousands of patients in research.
And, importantly, there’s far more at play than the vilified black legged tick: https://madisonarealymesupportgroup.com/2019/04/02/transmission-of-lyme-disease-lida-mattman-phd/
Mattman isolated living Borrelia spirochetes in mosquitoes, fleas, mites, semen, urine, blood, plasma and Cerebral Spinal Fluid. She discovered that this bacteria is dangerous because it can survive and spread without cell wall (L shape). Because L-forms do not possess cell wall, they are resistant to antibiotics that act upon the cell wall.
Others have found various ways Bb is transmitted as well:
Thursday, April 11, 2019 by: Ethan Huff
(Natural News) When it comes to the Religion of Vaccination, there’s one area of research that’s completely off-limits, and it encompasses looking into vaccine safety and effectiveness independently, and with an open mind. The reason for this, of course, is that every time a scientist dares to do this, he or she typically discovers that vaccines aren’t nearly as safe or effective as the medical police state claims – which instantly makes said scientist a target of the medical establishment, which has no qualms about doing almost anything in order to silence the truth.
One recent and prominent example of this type of medical tyranny involves Professor Chris Exley of Keele University in the United Kingdom, whose focused research into aluminum toxicity led him to conclude that childhood vaccines, many of which contain neurotoxic aluminum, can, in fact, cause autism – a discovery that, if you’ve been following independent vaccine science for any considerable period of time, is inherently “controversial” and a recipe for trouble.
Like Dr. Andrew Wakefield before him, Prof. Exley merely reported his findings in the interest of public health, as any good scientist would do. And in the process, he’s made himself enemy number one of the Vaccine Mafia, which is now trying to destroy his career and life by barring him from raising any further funding for his research endeavors.
In essence, Prof. Exley has officially blown the lid off the highly-destructive nature of aluminum in vaccines, indicating that this common chemical adjuvant has the potential to cause “severe and disabling” autism in children who are injected with it. And for violating the medical establishment’s never-to-be-challenged doctrine of “all vaccines are safe and effective,” Prof. Exley is now having to endure the ire of the priests and priestesses of the Cult of Vaccination, which are now out for blood.
Prof. Exley was one of the underwriters for an eye-opening 2017 study published in EBioMedicine, a journal associated with The Lancet, which found that underarm cosmetic products – mainly antiperspirant deodorants that contain aluminum – increase users’ risk of developing breast cancer.
He’s also studied other areas of aluminum toxicity similarly unrelated to vaccines – though vaccines eventually became a natural next-step for his particular area of focus. And rather than censor the progressive course of his research endeavors, Prof. Exley stuck true to science – and for doing this, he’s now paying a big price.
The good news, though, is that many people are on Prof. Exley’s side, and are working hard to get him funding from other sources. Some of his most ardently faithful followers have actually set up a GoFundMe page to help raise financial support for his continued research endeavors.
In light of the medical establishment’s continued betrayal of not only his work but also science at large, it’s up to everyday folks who care about truth to step up to the plate to make sure that parents know the truth – and more importantly, to ensure that as many children as possible are protected against toxic injections that could cause them lifelong harm.
“We’ve seen this drama unfold many times,” comments Age of Autism about this latest saga.
“A well respected doctor or researcher begins to ask questions about vaccine safety as a result of the science he or she conducts, and his career is adversely affected … [Prof. Exley’s] funding is dwindling and he needs our help.”
Also, be sure to check out the book How to End the Autism Epidemic by J.B. Handley.
Sources for this article include:
The following graph pretty much says it all:
The following information taken from the Organic Lifestyle magazine shows the censorship happening on anyone who departs from the accepted narrative that touts vaccines are safe: https://www.organiclifestylemagazine.com/doctor-asks-fda-to-reconsider-safe-levels-of-aluminum-gets-censored-and-suspended-on-medium
Dr. James Lyons-Weiler’s published a study, Reconsideration of the immunotherapeutic pediatric safe dose levels of aluminum, that says the recognized safe aluminum levels in vaccines are based on immune efficacy and ignore body weight. James says that several critical mistakes have been made in the consideration of pediatric dosing of aluminum and that safety inferences of vaccine doses of aluminum have relied solely on dietary (ingested, not injected) exposure studies of adult mice and rats.
On Day 1 of life, infants receive 17 times more aluminum than would be allowed if doses were adjusted per body weight.
The FDA states that 850 mcg of aluminum is safe for an adult. With his research, James found that a series of errors led to the guidelines that state 850 mcg of aluminum is safe for an adult.
The first serious problem (Problem #1) is that a provisionally tolerable weekly limit assumed to be safe was, by a series of errors and bad assumptions, transformed into a daily limit that appeared to be backed by studies. The studies used were not up to date, and the FDA’s determination used spurious estimates to transform safety information from dietary studies of adult mice into injected safe limits in human infants. These errors were made, in part, in the pediatric limit consideration by the FDA, who used outdated information not consistent with other organizations like World Health Organization.
To add to the confusion, the 1 mg/kg/week was also then changed to 2 mg/kg/week. The ATDSR used information from one study, assumed 1 mg/kg/week, adjusted using arbitrary functions that are without a doubt as good as a bad guess.
The provenance of these errors is reviewed further below, and in our newly published study.”
We came across this study last week on Medium. It has since been deleted, along with Jame’s account. We checked on web.archive.org to see if the page had been preserved; it had not. We searched Google, but it’s gone from search results, but we did find the article republished by James on LinkedIn.
This Open Letter originally appeared on Medium.com. Due to their censorship, it is ported here.= JLW. It is based on peer-reviewed studies.” – Dear FDA: Please Reconsider “Safe” Levels of Aluminum…
We also noticed that Jame’s Medium account has been suspended. And Bing is a little slower to eliminate the search results. If you want, click here to see their Cached version while it’s still available, but you can also read the full article republished on LinkedIn.
Articles on aluminum in vaccines: https://vactruth.com/?s=safe+levels+of+aluminum
For a great site on all things vaccine related. There is a list of scientific articles: https://vaccinepapers.org
According to the Centers for Disease Control and Prevention, about one in every 59 children in the U.S. is diagnosed with autism, up from one in every 150 in 2000. They report that
“about half a million people on the autism spectrum will become adults over the next decade, a swelling tide for which the country is unprepared.”
The apparent rise in autism spectrum disorder (ASD) and its stubborn resistance to treatment has spurred a legion of researchers to enter the field and explore the disability in innovative ways.
Currently, effective treatments for ASD include behavioral therapy, speech and social therapy, psychiatric medications, and dietary and nutritional approaches. However, no medical treatments have been approved to treat core symptoms of ASD such as social communication difficulties and repetitive behaviors.
One promising avenue of autism research involves the gut microbiome, which is the collection of microbes that lives in our intestines and helps us in many ways including digestion of our food, training our immune system and preventing overgrowth of harmful bacteria. Recent research suggests our gut microbiomes also affect brain communication and neurological health. Worldwide, interest is growing in the idea that changes in normal gut microbiota may be responsible for triggering a vast range of diseases.
In a new study, “Long-term benefit of Microbiota Transfer Therapy in Autism Symptoms and Gut Microbiota,” published in Scientific Reports, Arizona State University researchers Rosa Krajmalnik-Brown, Ph.D., James Adams, Ph.D, and lead author Dae-Wook Kang, Ph.D, demonstrate long-term beneficial effects for children diagnosed with ASD through a revolutionary technique known as Microbiota Transfer Therapy (MTT), a special type of fecal transplant originally pioneered by Dr. Thomas Borody, an Australian gastroenterologist.
At two years post-treatment, most of the initial improvements in gut symptoms remained. In addition, parents reported a slow steady reduction of ASD symptoms during treatment and over the next two years. A professional evaluator found a 45% reduction in core ASD symptoms (language, social interaction and behavior) at two years post-treatment compared to before treatment began.
“We are finding a very strong connection between the microbes that live in our intestines and signals that travel to the brain,” said Krajmalnik-Brown, a professor at the Biodesign Swette Center for Environmental Biotechnology at the Biodesign Institute and ASU’s School for Sustainable Engineering and the Built Environment. “Two years later, the children are doing even better, which is amazing.”
“Many kids with autism have gastrointestinal problems, and some studies, including ours, have found that those children also have worse autism-related symptoms,” said Krajmalnik-Brown. “In many cases, when you are able to treat those gastrointestinal problems, their behavior improves.”
Roughly 30-50% of all people with autism have chronic gastrointestinal (GI) problems, primarily constipation and/or diarrhea that can last for many years. That chronic discomfort and pain can cause irritability, decreased attention and learning, and negatively impact behavior.
An earlier study with only vancomycin (an antibiotic) had found major temporary improvements in GI and autism symptoms, but the benefits were lost a few weeks after treatment stopped despite use of over-the-counter probiotics.
So, the question at hand was what’s going on in the gut, and how does it affect both physical and behavioral symptoms of autism, and how can we develop a long-lasting treatment?
Krajmalnik-Brown, Kang and Adams have shown that by transferring healthy microbiota to individuals lacking certain gut bacteria, it is possible to “donate” a more diverse set of bacteria into the patient and improve gut health.
In Australia, Fecal Microbiota Transplantation (FMT) was initially developed by Borody. At his Centre for Digestive Diseases in Sydney, Borody has overseen more than 18,000 FMTs for various disorders since 1987. He pioneered in Australia the use of FMT for colitis and Clostridium difficile infection, and was the first to use oral FMT to treat children with ASD. Only one dose of FMT is usually enough to cure C. Difficile infections, but his patients with autism were far harder to treat. He discovered that three months of daily FMT was required to treat his autism patients, but eventually resulted in significant improvements in both GI and autism symptoms.
Based on his experience with his patients, Borody led the design of the clinical treatment used at ASU for this study. The MTT approach involves 10 weeks of treatment, including pre-treatment with vancomycin, a bowel cleanse, a stomach acid suppressant, and fecal microbiota transfer daily for seven to eight weeks.
The initial open-label study, led by Krajmalnik-Brown and Adams, and published in the journal Microbiome in 2017, concluded that “this exploratory, extended-duration treatment protocol thus appears to be a promising approach to alter the gut microbiome and improve GI and behavioral symptoms of ASD. Improvements in GI symptoms, ASD symptoms, and the microbiome all persisted for at least eight weeks after treatment ended, suggesting a long-term impact.” The present study now shows the benefits are extended beyond eight weeks to at least two years post-treatment.
The ASU team compared differences in the microbiome of children with autism compared to typically developing children. At the start of the study, children with autism were found to have lower diversity in their respective gut microbes and were depleted of certain strains of helpful bacteria, such as Bifidobacteria and Prevotella.
“Kids with autism are lacking important beneficial bacteria, and have fewer options in the bacterial menu of important functions that bacteria provide to the gut than typically developing kids,” Krajmalnik-Brown said.
FMT treatment substantially increased microbial diversity and the presence of helpful bacteria in the gut, such as Bifidobacteria and Prevotella. After two years, diversity was even higher and the presence of beneficial microbes remained.
“We originally hypothesized that our therapy would be efficient to transform the dysbiotic gut microbiome toward a healthy one. In our original paper in 2017, we reported an increase in gut diversity together with beneficial bacteria after MTT, and after two years, we observed diversity was even higher and the presence of beneficial microbes remained,” Kang said.
He added that this may be one of the reasons for success in improving the gut health, but further mechanistic studies are warranted to define specific roles of gut microbes in the context of autism.
The work done at ASU is not only about treating patients but also about learning from the treatment in order to develop better formulations and optimize dosing.
“Understanding which microbes and chemicals produced by the microbes are driving these behavioral changes is at the heart of our work,” Krajmalnik-Brown said. The team’s new publication reports that the study demonstrated that two years after treatment stopped the participants still had an average of a 58% reduction in GI symptoms compared to baseline. In addition, the parents of most participants reported “a slow but steady improvement in core ASD symptoms.”
“Every family completed the study, and every family returned two years later for a follow-up evaluation,” said Adams, citing the families’ dedication to the research. “The treatment was generally well-tolerated with minimal adverse effects.”
“This is a world-first discovery that when we treated the gut bacteria in these children during our clinical trial two years ago to reset their microbiome with FMT, positive results are still continuing to be improving two years from the original treatments. I would call it the highest improvement in a cohort that anyone has achieved for autism symptoms,” said Borody.
Professional evaluation revealed a 45% decrease in ASD symptoms compared to baseline. Researchers note that although there may be some placebo effect, much of that effect appears to be real. At the start of the study, 83% of participants were rated as “severe” autism. At the end of the study, only 17% were “severe,” 39% were “mild/moderate,” and 44% were below the cut-off for mild ASD.
Greg Caporaso, at Northern Arizona University, a leading expert in microbiome data science and a co-author on these studies, helped to analyze the microbiome data to better understand bacterial changes as a result of MTT.
“Drs. Krajmalnik-Brown, Kang and I are excited about the results, but we want to caution the public that we need larger clinical trials for this to become an FDA-approved treatment,” said Adams. Professional expertise is required for safe and effective treatment.
MTT improves GI distress by introducing key strains of beneficial bacteria and helping to raise levels of biodiversity within the gut, boosting health overall.
Adams has both professional and personal reasons for doggedly pursuing ways to help children with autism because he knows the situation first-hand. His daughter was diagnosed with autism just before her third birthday. Adams, a President’s Professor at ASU’s School for Engineering of Matter, Transport and Energy, and the chair of Materials Sciences, is also president of the Autism Society of Greater Phoenix, the largest parent support group in Arizona.
“Dr. James Adams is the reason why I started working on autism,” Krajmalnik-Brown said. “I had the methods to do all of the measurements and assessments in the microbiome part of the work, and he had the autism knowledge.”
Adams recruited patients, supervised clinical work and ASD assessments, and guided the patients through the trials, and Krajmalnik-Brown led the microbiome evaluations and helped plan the study.
All of the participants in the study exhibited chronic GI symptoms from infancy, including chronic constipation and/or chronic diarrhea. The treatment benefits extended beyond their physical symptoms, even causing some parents to note how much their children’s behavior had improved over time.
“It is very unusual to see steady gradual improvement after the conclusion of any treatment,” said Adams. “We only conducted the long-term follow-up study after several families told us that their child was continuing to improve significantly.”
Krajmalnik-Brown stated that the data suggests that the MTT intervention transformed the gut environment into a healthier status, leading to long-term benefit on both GI and ASD symptoms.
Adams said many of the participants in the trial shared common traits, including
All of these lead to limited biodiversity in their gut bacteria. Due to the open label nature of the study and the small sample size used, more research is needed in order to verify the usefulness of MTT as a therapeutic.
The initial study involved a “first-generation” estimate as to optimal dose and duration of treatment, and it was enough for 90% of the children to have substantial benefit. The team is now working on optimizing the dosing and duration to try to improve benefits even more, and to determine if booster doses may be needed in some cases.
Register here: https://autismone.ticketspice.com/autism-one-2019-conference
The most rewarding educational and networking experience you can have at any autism conference! An exceptional value as you gather new hope, answers, help, and direction.
New to the autism diagnosis? Come hear the “Newly Diagnosed” track just for you!
Yearning to learn more? Hear the “Biomedical Research and Treatments” track!
This conference will help you answer and understand important concepts:
On the autism journey a little while? Come hear the latest research and healing information!
Medical professional? Hear renowned researchers present the latest cutting-edge autism research.
The AutismOne 2019 Conference will be held May 22-26, 2019, at the Loews Chicago O’Hare Hotel in Rosemont, IL.
“AutismOne always has the cutting-edge information years ahead of any other autism conference. You hear it first at AutismOne.” ~Janet Cakir, PhD
WEDNESDAY, MAY 22, LECTURES:
THURSDAY, MAY 23, LECTURES, MOVIES, PANELS:
FRIDAY, MAY 24, LECTURES AND PANELS:
SATURDAY, MAY 25, LECTURES AND PANELS:
SUNDAY, MAY 26, LECTURES:
See list of speakers: https://autismoneconference.com/conference_speakers.html Erica Linn, MSN & Dr. Greg Brown MD from Serenity Health in Wisconsin will be speakers at the conference. Dr. Brown treats children and adults with Lyme/MSIDS as well as PANS/PANDAS. He’s stated that up to 80% of his autistic and PANS/PANDAS patients are infected with Lyme/MSIDS.
https://madisonarealymesupportgroup.com/2017/10/09/today-is-panspandas-awareness-day/ Trifiletti officially diagnosed Carson with PANS, not PANDAS, due to the active co-infections found in his blood work: mycoplasma, the bacteria that causes pneumonia; coxsackie — the virus causing Hand, Foot and Mouth disease; streptococcus, the bacteria causing strep throat; bartonella and babesia — a bacteria and parasite related to Lyme disease; and yeast, Melissa Spears said.
Instead of attacking these infections, Carson’s antibodies were instead going after his brain.